Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS)

Nivedita Nagachar, Colin Ratledge

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Because of the emergence of strains of Mycobacterium tuberculosis resistant to first-line antituberculosis agents, one of the second-line drugs, p-aminosalicylate (PAS), has regained importance in the treatment of tuberculosis. The mode of action of PAS, however, remains controversial as to whether it inhibits mycobactin or folate biosynthesis. To unravel this, we have studied the effect of PAS on wild-type Mycobacterium smegmatis and its mutants (gene knockouts of the salicylate pathway - trpE2, entC and entD). The wild type had no sensitivity to PAS (MIC>400 μg mL-1), whereas the mutants were hypersensitive, with 1 μg mL-1 inhibiting growth. The sulphonamides, trimethoprim and dapsone, had little effect on the growth of either the mutants or the wild type. In addition, PAS at 0.5 μg mL -1 increased the accumulation of salicylate with the wild type and mutants. These results support our hypothesis that PAS targets the conversion of salicylate to mycobactin, thus preventing iron acquisition from the host.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalFEMS Microbiology Letters
Volume311
Issue number2
DOIs
StatePublished - Oct 1 2010

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS)'. Together they form a unique fingerprint.

  • Cite this